Endometrial cancer is the sixth most common cancer in women worldwide, with a 132% increase in incidence over the last 30 years. Despite this, mortality rates have decreased due to advancements in early diagnosis and treatment. Recent advances in understanding the molecular drivers of endometrial cancer have led to the development of targeted interventions for primary disease prevention. Minimally invasive tests using protein and DNA biomarkers and cytology have improved early diagnosis, while molecular classification has guided adjuvant treatment decisions. Advanced and recurrent disease management has been revolutionized by debulking surgery and targeted treatments, particularly immunotherapy. This review summarizes recent advances in endometrial cancer prevention, diagnosis, and treatment and identifies areas for future research, including the need for large-scale clinical trials to validate new diagnostic techniques and the development of predictive biomarkers for targeted therapies.Endometrial cancer is the sixth most common cancer in women worldwide, with a 132% increase in incidence over the last 30 years. Despite this, mortality rates have decreased due to advancements in early diagnosis and treatment. Recent advances in understanding the molecular drivers of endometrial cancer have led to the development of targeted interventions for primary disease prevention. Minimally invasive tests using protein and DNA biomarkers and cytology have improved early diagnosis, while molecular classification has guided adjuvant treatment decisions. Advanced and recurrent disease management has been revolutionized by debulking surgery and targeted treatments, particularly immunotherapy. This review summarizes recent advances in endometrial cancer prevention, diagnosis, and treatment and identifies areas for future research, including the need for large-scale clinical trials to validate new diagnostic techniques and the development of predictive biomarkers for targeted therapies.